Article
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Cancer science - 1 Feb 2020
Lei Lei, Wang Wen-Xian, Zhu You-Cai, Li Jin-Luan, Fang Yong, Wang Hong, Zhuang Wu, Zhang Yin-Bin, Wang Li-Ping, Fang Mei-Yu, Xu Chun-Wei, Wang Xiao-Jia, Lv Tang-Feng, Song Yong
Abstract excerpt
The incidence of epidermal growth factor receptor uncommon mutation (EGFRum) is relatively low and patients harboring EGFRum are resistant to the first-generation tyrosine kinase inhibitors (TKI). However, the mechanism of primary resistance remains unclear. Medical records of 98 patients who had never been treated by TKI and who accepted icotinib treatment were collected and followed. The circulating tumor DNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.